SMSusan Christine Massey

Susan Christine Massey

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Susan Christine Massey has a total of 149 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Reproducible autosomal gene expression changes with loss of typical X and Y complement across tumor types

    by Seema B. Plaisier, Robert Phavong, Mason Farmwald, Mariah Lee, Teagen Allen, Malli Swamy, Ilsa Rodriguez, MacKenzie Wells, Nadia Phaneuf, Susan Christine Massey, et al.

    Although there are known sex differences in cancer incidence, severity, and treatment, the sex chromosomes are typically excluded from genomic analyses because of the unique technical challenges associated with assessing their copy number, sequence variation, and expression. Here we assess sex chromosome complement in three widely-used human genomics datasets from normal (non-cancerous) tissues, primary tumors, and cancer cell lines and study the effects on genome-wide gene expression. Expected sex chromosome complements based on reported patient sex were observed in non-cancerous tissues, but about half of tumors and cancer cell lines showed loss of typical sex chromosome gene expression across tissue types with three categories: loss of chromosome Y (LOY), loss of chromosome X (LOX) and reactivation of the inactive X chromosome (XaXa). Genes consistently differentially expressed in tumors with loss of chromosome X, loss of chromosome Y, or loss of X chromosome inactivation are associated with the hallmarks of cancer and include both sex-linked and autosomal genes from nearly all chromosomes, druggable genes, and genes with molecular functions relevant to cancer signaling, such as kinase activity. Strikingly, tumors that are X0, including tumors from female patients that have lost an X chromosome and tumors from male patients that have lost a Y chromosome, cluster together by gene expression profile. Patients with tumors that have LOX or LOY had poorer survival outcomes compared to those with tumors that had maintained their sex chromosome complement. Further, LOX and LOY eliminates nearly all of the differential gene expression between tumors from different patient sexes, affecting sex chromosomal and autosomal gene expression. Going forward, considering patient sex as well as the entire genome, including assessment of the sex chromosome complement, will provide additional insights into personalized tumor etiology, progression, treatment, and patient outcome. Teaser: Loss of typical sex chromosome complement is present in primary tumors and cancer cell lines across tissue types. We identify consistent autosomal gene expression changes across multiple cancers when the sex chromosome complement is altered, and show that loss of sex chromosomes reduces tumor gene expression differences between patient sexes. We show that loss of sex chromosomes is also associated with poorer patient survival.

  • Open Access

    Abstract 4081: Leveraging single-cell RNA sequencing data to design multi-targeting SeekRRNA therapeutics

    by Susan Massey, Richard Hsiao, Shweta Yadav, David Azorsa, Spyro Mousses, Jeffrey A. Kiefer

    SeekR™ chimeric molecules consist of dual flanking RNA aptamers designed to bind specific proteins (BINDERS), joined by a double stranded RNA bridge that encodes multiple siRNAs designed to silence select disease target genes (SILENCERS). Aptamers are folded nucleic acid chains that act much like chemical antibodies in that they can bind proteins in a sequence-specific manner. By identifying RNA aptamers capable of seeking and binding to specific cell surface protein receptors, SeekR™ RNA therapeutics can be engineered to self-deliver to a particular receptor defined tissue type. For example, a SeekR™ can be directed to prostate tumors that selectively express PSMA. The combination of two RNA aptamer binders with two siRNA silencers thus enables the selective delivery of the siRNAs to tumor cells expressing the binder target, wherein it directs sequence-specific silencing of cancer target genes. To identify and prioritize the right combination of SeekR targets, we have taken advantage of single-cell sequencing (scRNA-seq) data sets. By analyzing scRNA-seq data, we can identify specific cell populations within tumors to co-target with an aptamer and siRNA. We leveraged several publicly available colon and non-small cell lung cancer scRNA data sets for this analysis. A custom analysis pipeline was applied to these data to identify specific cell types within tumor samples. We then profiled specific cancer targets and determined percentages of target co-expression within a single tumor compared to normal cells. This provides information for cell-type-specific targeting to reduce potential toxicity within non-tumor tissue. In addition to targeting aptamers, we performed ligand-receptor analyses to prioritize specific siRNA targets in particular cell types within the tumor environment. This analysis revealed novel combinations of binders and silencers that will more precisely deliver the right multi-targeted gene silencing to the correct cell types. In summary, scRNA-seq data provide a rich resource of data to direct SeekR™ development and optimization. Citation Format: Susan Massey, Richard Hsiao, Shweta Yadav, David Azorsa, Spyro Mousses, Jeffrey A. Kiefer. Leveraging single-cell RNA sequencing data to design multi-targeting SeekRRNA therapeutics [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 4081.

  • Open Access

    Sex Differences in MRI-Based Metrics of Glioma Invasion and Brain Mechanics

    by Barrett J. Anderies, Sara F. Yee, Pamela R. Jackson, Cassandra R. Rickertsen, Andrea J. Hawkins-Daarud, Sandra K. Johnston, Kamala R. Clark-Swanson, Joseph M. Hoxworth, Yuan Le, Yuxiang Zhou, et al.

    Gliomas are brain tumors characterized by highly variable growth patterns. Magnetic resonance imaging (MRI) is the cornerstone of glioma diagnosis and management planning. However, glioma features on MRI do not directly correlate with tumor cell distribution. Additionally, there is evidence that glioma tumor characteristics and prognosis are sex-dependent. Magnetic resonance elastography (MRE) is an imaging technique that allows interrogation of tissue stiffness in-vivo and has found utility in the imaging of several cancers. We investigate the relationship between MRI features, MRE features, and growth parameters derived from an established mathematical model of glioma proliferation and invasion. Results suggest that both the relationship between tumor volume and tumor stiffness as well as the relationship between the parameters derived from the mathematical model and tumor stiffness are sex-dependent. These findings lend evidence to a growing body of knowledge about the clinical importance of sex in the context of cancer diagnosis, prognosis and treatment.

  • Sex differences in health and disease: A review of biological sex differences relevant to cancer with a spotlight on glioma

    by Susan Christine Massey, Paula Whitmire, Tatum E. Doyle, Joseph E. Ippolito, Maciej M. Mrugala, Leland S. Hu, Peter Canoll, Alexander R.A. Anderson, Melissa A. Wilson, Susan M. Fitzpatrick, et al.


  • Open Access

    Image-based metric of invasiveness predicts response to adjuvant temozolomide for primary glioblastoma

    by Susan Christine Massey, Haylye White, Paula Whitmire, Tatum Doyle, Sandra K Johnston, Kyle W Singleton, Pamela R Jackson, Andrea Hawkins-Daarud, Bernard R Bendok, Alyx B Porter, et al.

    Temozolomide (TMZ) has been the standard-of-care chemotherapy for glioblastoma (GBM) patients for more than a decade. Despite this long time in use, significant questions remain regarding how best to optimize TMZ therapy for individual patients. Understanding the relationship between TMZ response and factors such as number of adjuvant TMZ cycles, patient age, patient sex, and image–based tumor features, might help predict which GBM patients would benefit most from TMZ, particularly for those whose tumors lack O6–methylguanine–DNA methyltransferase (MGMT) promoter methylation. Using a cohort of 90 newly–diagnosed GBM patients treated according to the standard of care, we examined the relationships between several patient and tumor characteristics and volumetric and survival outcomes during adjuvant chemotherapy. Volumetric changes in MR imaging abnormalities during adjuvant therapy were used to assess TMZ response. T1Gd volumetric response is associated with younger patient age, increased number of TMZ cycles, longer time to nadir volume, and decreased tumor invasiveness. Moreover, increased adjuvant TMZ cycles corresponded with improved volumetric response only among more nodular tumors, and this volumetric response was associated with improved survival outcomes. Finally, in a subcohort of patients with known MGMT methylation status, methylated tumors were more diffusely invasive than unmethylated tumors, suggesting the improved response in nodular tumors is not driven by a preponderance of MGMT methylated tumors. Our finding that less diffusely invasive tumors are associated with greater volumetric response to TMZ suggests patients with these tumors may benefit from additional adjuvant TMZ cycles, even for those without MGMT methylation.


  • Open Access

    From cells to tissue: How cell scale heterogeneity impacts glioblastoma growth and treatment response

    by Jill A Gallaher, Susan C Massey, Andrea Hawkins-Daarud, Sonal S Noticewala, Russell C Rockne, Sandra K Johnston, Luis Gonzalez-Cuyar, Joseph Juliano, Orlando Gil, Kristin R Swanson, et al.

    Glioblastomas are aggressive primary brain tumors known for their inter- and intratumor heterogeneity. This disease is uniformly fatal, with intratumor heterogeneity the major reason for treatment failure and recurrence. Just like the nature vs nurture debate, heterogeneity can arise from intrinsic or environmental influences. Whilst it is impossible to clinically separate observed behavior of cells from their environmental context, using a mathematical framework combined with multiscale data gives us insight into the relative roles of variation from different sources. To better understand the implications of intratumor heterogeneity on therapeutic outcomes, we created a hybrid agent-based mathematical model that captures both the overall tumor kinetics and the individual cellular behavior. We track single cells as agents, cell density on a coarser scale, and growth factor diffusion and dynamics on a finer scale over time and space. Our model parameters were fit utilizing serial MRI imaging and cell tracking data from ex vivo tissue slices acquired from a growth-factor driven glioblastoma murine model. When fitting our model to serial imaging only, there was a spectrum of equally-good parameter fits corresponding to a wide range of phenotypic behaviors. When fitting our model using imaging and cell scale data, we determined that environmental heterogeneity alone is insufficient to match the single cell data, and intrinsic heterogeneity is required to fully capture the migration behavior. The wide spectrum of in silico tumors also had a wide variety of responses to an application of an anti-proliferative treatment. Recurrent tumors were generally less proliferative than pre-treatment tumors as measured via the model simulations and validated from human GBM patient histology. Further, we found that all tumors continued to grow with an anti-migratory treatment alone, but the anti-proliferative/anti-migratory combination generally showed improvement over an anti-proliferative treatment alone. Together our results emphasize the need to better understand the underlying phenotypes and tumor heterogeneity present in a tumor when designing therapeutic regimens. Glioblastoma, the most common primary brain tumor, is an aggressive and difficult to treat cancer. A key reason is that the tumors can be very heterogeneous, consisting of many different mutants driving distinct cell behaviors. We believe that treatments for this disease could be significantly improved by understanding and quantifying the functional impact of heterogeneity within the tumor. From a clinical standpoint, the larger tissue-scale dynamics, like growth rate, can be informed from serial MRI imaging, while the cell-scale heterogeneity, can be informed by analysis of biopsies. In this work, we combined information from both scales using a mathematical framework and multiscale data from an animal model of glioblastoma. We found that a wide range of potential tumor compositions matched imaging data alone, as a result the model predicts a wide variety of responses to treatment. Using both imaging and cell-scale data narrowed the range of possible tumor compositions and better predicted responses to treatment. The mathematical model also predicted that while targeting migration alone did not slow tumor growth (in fact it drove a more proliferative tumor), an anti-proliferative/anti-migratory treatment combination improved treatment response.


  • Open Access

    Quantifying glioblastoma drug response dynamics incorporating resistance and blood brain barrier penetrance from experimental data

    by Susan Christine Massey, Javier C. Urcuyo, Bianca Maria Marin, Jann N. Sarkaria, Kristin R. Swanson

    Many drugs investigated for the treatment of glioblastoma (GBM) have had poor clinical outcomes, as their efficacy is dependent on adequate delivery to sensitive tumor cell populations, which is limited by the blood-brain barrier (BBB). Further complicating evaluation of therapeutic efficacy, tumors can become resistant to anti-cancer drugs, and it can be difficult to gauge the extent to which BBB limitations and resistance each contribute to a drug’s failure. To address this question, we developed a minimal mathematical model to characterize these elements of overall drug response, informed by time-series bioluminescence imaging data from a treated patient-derived xenograft (PDX) experimental model. By fitting this mathematical model to a preliminary dataset in a series of nonlinear regression steps, we estimated parameter values for individual PDX subjects that correspond to the dynamics seen in experimental data. Using these estimates, we performed a parameter sensitivity analysis using Latin hypercube sampling and partial rank correlation coefficients. Results from this analysis combined with simulation results suggest that BBB permeability may play a slightly larger role in therapeutic efficacy than drug resistance. Our model and fitting technique to estimate parameters from data may be a useful tool in aiding further exploration of these challenges in future studies of drug efficacy with larger datasets.


  • Sex Differences in Predicting Fluid Intelligence of Adolescent Brain from T1-Weighted MRIs

    by Sara Ranjbar, Kyle W. Singleton, Lee Curtin, Susan Christine Massey, Andrea Hawkins-Daarud, Pamela R. Jackson, Kristin R. Swanson


  • Open Access

    From cells to tissue: How cell scale heterogeneity impacts glioblastoma growth and treatment response

    by Jill A. Gallaher, Susan C. Massey, Andrea Hawkins-Daarud, Sonal S. Noticewala, Russell C. Rockne, Sandra K. Johnston, Luis Gonzalez-Cuyar, Joseph Juliano, Orlando Gil, Kristin R. Swanson, et al.

    Glioblastomas are aggressive primary brain tumors known for their inter- and intratumor heterogeneity. This disease is uniformly fatal, with intratumor heterogeneity the major reason for treatment failure and recurrence. Just like the nature vs nurture debate, heterogeneity can arise from heritable or environmental influences. Whilst it is impossible to clinically separate observed behavior of cells from their environmental context, using a mathematical framework combined with multiscale data gives us insight into the relative roles of variation from inherited and environmental sources. To better understand the implications of intratumor heterogeneity on therapeutic outcomes, we created a hybrid agent-based mathematical model that captures both the overall tumor kinetics and the individual cellular behavior. We track single cells as agents, cell density on a coarser scale, and growth factor diffusion and dynamics on a finer scale over time and space. Our model parameters were fit utilizing serial MRI imaging and cell tracking data from ex vivo tissue slices acquired from a growth-factor driven glioblastoma murine model. When fitting our model to serial imaging only, there was a spectrum of equally-good parameter fits corresponding to a wide range of phenotypic behaviors. This wide spectrum of in silico tumors also had a wide variety of responses to an application of an antiproliferative treatment. Recurrent tumors were generally less proliferative than pre-treatment tumors as measured via the model simulations and validated from human GBM patient histology. When fitting our model using imaging and cell scale data, we determined that heritable heterogeneity is required to capture the observed migration behavior. Further, we found that all tumors increased in size after an anti-migratory treatment, and some tumors were larger after a combination treatment than with an anti-proliferative treatment alone. Together our results emphasize the need to understand the underlying phenotypes and tumor heterogeneity in designing therapeutic regimens.

  • Open Access

    Quantifying glioblastoma drug penetrance from experimental data

    by Susan Christine Massey, Javier Urcuyo, Bianca Maria Marin, Jann Sarkaria, Kristin R. Swanson

    Poor clinical trial outcomes for glioblastoma (GBM) can be attributed to multiple possible causes. GBM is heterogeneous, such that there is a chance of treatment–resistant cells coming to predominate the tumor, and due to the blood brain barrier (BBB) it is also possible that therapy was inadequately delivered to the tumor. Mathematically modeling the dynamics of therapeutic response in patient–derived xenografts (PDX) and fitting the mathematical model to bioluminescence imaging flux data, we may be able to assess the degree to which both drug resistance and drug penetrance are driving varied responses to these therapies.